TVTX stock jumped 32% in a single session after the FDA’s full approval of FILSPARI in FSGS on April 14, 2026 — and then kept going. TVTX stock is trading at $41.10 — we rate it a Buy with a $44 average price target from 10 analysts, and the setup is compelling at current levels given FILSPARI’s newly cleared path into a second rare-kidney-disease indication. The TVTX stock price is up roughly 51% over 30 days, yet the sell-side high target from Guggenheim at $54 still implies 31% additional upside if commercial execution holds.
| Metric | Value |
|---|---|
| Current Price | $41.10 |
| 52-Week Range | $14.85 – $42.80 |
| Market Cap | ~$3.9B |
| P/E Ratio | n/m (net loss) |
| EPS (TTM) | -$2.86 |
| Analyst Consensus | Buy |
| Average Price Target | $44.00 |
Table of Contents
- Key Takeaways for TVTX Stock Forecast 2026
- What Is Travere Therapeutics (TVTX Stock)?
- Recent TVTX Stock Price Performance and FDA Catalyst
- TVTX Stock Forecast 2026: Valuation Analysis
- Bullish and Bearish Analyst Opinions on Travere Therapeutics
- TVTX Stock Analyst Price Targets and Ratings
- FILSPARI Commercial Opportunity and TVTX Stock Forecast 2026
- FAQs About TVTX Stock Forecast 2026
Key Takeaways for TVTX Stock Forecast 2026
- Price and verdict: TVTX trades at $41.10 with a Buy consensus and a $44 average price target — roughly 7% implied upside with meaningful optionality to $54.
- Key stat: FILSPARI is now the first and only FDA-approved medicine for focal segmental glomerulosclerosis (FSGS), a rare kidney disease affecting 30,000+ U.S. patients.
- Bull case: Leerink projects FILSPARI can reach $1 billion in peak FSGS sales and $2 billion across FSGS + IgA nephropathy combined.
- Bear case: Shares are up 173% over 12 months, execution risk on commercial ramp is real, and the stock is highly concentrated in a single asset.
- Bottom line: The TVTX stock forecast 2026 setup is compelling at current levels — FDA approval has validated the underlying thesis, and Street targets still imply upside.
What Is Travere Therapeutics (TVTX Stock)?
Travere Therapeutics (NASDAQ: TVTX) is a San Diego-based biopharmaceutical company focused on rare kidney and metabolic diseases. The company’s lead asset is FILSPARI (sparsentan), a first-in-class dual endothelin angiotensin receptor antagonist originally approved for IgA nephropathy (IgAN) in 2023 and now granted full FDA approval in April 2026 for focal segmental glomerulosclerosis (FSGS). FSGS is a rare, progressive kidney disorder that can lead to end-stage kidney disease — FILSPARI is the first and only medicine approved by the FDA to treat it.
Travere’s other commercial assets include Thiola (for cystinuria) and Chenodal/Cholbam (rare metabolic conditions), though FILSPARI is now the clear revenue driver. The FSGS approval expands FILSPARI’s addressable patient population to more than 100,000 patients in the U.S., including the existing IgAN franchise and the newly cleared 30,000+ FSGS patients. The company’s commercial model relies on rare-disease specialist sales infrastructure and patient identification programs, with list pricing in the $160,000–$180,000 annual range — standard for orphan-designated rare kidney drugs.
From a financial perspective, Travere posted trailing-twelve-month revenue near $275 million (pre-FSGS indication) and continued to operate at a net loss as commercial investment scaled alongside IgAN launch. The company holds a royalty-bearing license on FILSPARI from Ligand Pharmaceuticals, which affects gross margin but was long factored into sell-side models. The path to operating profitability depends on FILSPARI’s commercial ramp, and that ramp is what every serious TVTX stock forecast 2026 now underwrites.
Recent TVTX Stock Price Performance and FDA Catalyst
Travere stock has been one of the sharpest movers in mid-cap biotech. The 7-day share price return is 40.78%, the 30-day return is 51.22%, and the 1-year total shareholder return sits at 173.26%. Shares closed at $30.70 on April 13, 2026, then surged 32% to $41.10 on April 14 after the FDA approval announcement. Volume on approval day exceeded 12 million shares versus a 50-day average under 3 million — a textbook institutional re-rating flow.
The 52-week range of $14.85 to $42.80 illustrates the journey. Shares bottomed in 2025 on FSGS Phase 3 readout timing uncertainty and on broader rare-disease biotech de-rating. Sentiment inflected positively once the FDA accepted the FSGS supplemental new drug application (sNDA) for priority review in late 2025, and the April approval delivered the final leg of the move. The current $41.10 print is roughly 4% below the 52-week high of $42.80, indicating the market is still digesting the approval rather than pricing in the full commercial opportunity.
For any honest TVTX stock price analysis, the practical reference levels are clear. Support sits at $35 (the approval-day open), with secondary support at $28 (pre-approval consolidation). Resistance aligns with the $42.80 recent high, and a sustained break above that zone would target the $48–$54 band where Citi and Guggenheim see fair value. Short interest fell from roughly 12% of float to 8% through the approval event, meaning some of the easy short-squeeze fuel has already been consumed.
TVTX Stock Forecast 2026: Valuation Analysis
Traditional earnings-based valuation doesn’t apply to TVTX stock today — the company is operating at a loss. The TVTX stock forecast 2026 needs a combination of peak-sales NPV and EV/revenue multiples to arrive at a reasonable fair value. At a $3.9 billion enterprise value and Leerink’s projected $2 billion combined peak sales for FILSPARI, Travere currently trades at roughly 2x peak sales — well below rare-disease peers that typically trade at 4–6x peak sales at launch inflection.
On a peak-sales NPV basis with a 10% discount rate and 25% probability weighting on upside scenarios (international expansion, additional indications), intrinsic value for TVTX comes in around $46 per share. That is higher than the $44 sell-side average and roughly in line with the Citigroup $53 target. The narrative fair value from Simply Wall St pins intrinsic value at $42.50, slightly above today’s $41.10 close. Taken together, these methods converge in the $42–$54 zone — consistent with an underlying TVTX stock forecast 2026 that sees modest upside with significant commercial optionality.
| Valuation Approach | Assumptions | Implied Price |
|---|---|---|
| Sell-side average | FILSPARI base-case ramp, orphan pricing | $44.00 |
| Peak-sales NPV (base case) | $2B peak sales, 10% WACC, 90% POS | ~$46 |
| Narrative fair value | Rare-disease market benchmark | $42.50 |
| Bull case (Guggenheim) | International expansion + third indication | $54.00 |
| Bear case | Slow launch, payer pushback on price | $28–$32 |
The EV/peak-sales ratio is the cleanest single metric. At current levels, TVTX trades near 2x peak sales — Alnylam Pharmaceuticals historically commanded 5x at comparable launch stages, and Ionis Pharmaceuticals traded at 4x. This gap suggests the TVTX stock forecast 2026 still has room to close toward peer multiples if the early FSGS launch weeks deliver prescription numbers consistent with the pre-approval patient survey work.
Bullish and Bearish Analyst Opinions on Travere Therapeutics
The bullish and bearish analyst opinions on Travere Therapeutics skew bullish post-approval, with 8 Buy ratings, 2 Holds, and 0 Sells across the covering universe. Citi raised its target from $48 to $53, citing the FSGS approval validating commercial execution and opening a second orphan indication. Guggenheim hiked its target from $49 to $54, pointing to Leerink’s $2 billion combined peak-sales projection. JPMorgan maintained its Overweight rating with a $41 target, pricing in launch execution risk on both IgAN and FSGS fronts simultaneously.
| Bull Case for TVTX | Bear Case for TVTX |
|---|---|
| First-and-only FDA approved FSGS therapy | Single-product concentration in FILSPARI |
| Dual indication (IgAN + FSGS) = $2B peak sales | Stock up 173% over 12 months — entry risk |
| Orphan exclusivity and high list pricing | Payer pushback on $160k+ annual pricing |
| 30,000+ FSGS patient TAM in US alone | Commercial ramp timing still unproven |
| Pipeline optionality in metabolic diseases | Ligand royalty affects gross margin |
The bear case most worth engaging is not valuation — it is commercial. Travere’s sales force expansion into FSGS-treating nephrologists requires rapid scale-up, and the diagnostic journey for FSGS is more fragmented than IgAN. If prescription uptake in Q2 and Q3 2026 misses Street expectations, the stock could give back 15–25% of recent gains. Conversely, if FSGS ramps in line with IgAN’s launch curve (which reached $40M quarterly within 18 months of approval), the TVTX stock forecast 2026 has room to revisit the $50+ zone.
A quieter bull argument: Travere now presents as a credible take-out target. Mid-cap kidney and rare-disease specialist franchises have been acquired at roughly 3–4x peak sales in recent years. At 2x peak sales today, TVTX screens as the cleanest remaining dedicated nephrology play outside of Vertex Pharmaceuticals‘ kidney pipeline and large-cap Biogen‘s recently expanded rare-disease footprint.
TVTX Stock Analyst Price Targets and Ratings
The 10-analyst coverage universe for TVTX stock clustered tightly in the $42–$54 range after the FSGS approval. The average price target stands at $44.00 with a high of $54.00 (Guggenheim) and a low of $31.00 (pre-approval standout). Median target is $42.50 — essentially today’s close. The distribution is characteristic of a freshly re-rated stock where analysts have moved in the same direction at different speeds.
| Firm | Rating | Price Target | Implied Upside |
|---|---|---|---|
| Guggenheim | Buy | $54.00 | +31% |
| Citigroup | Buy | $53.00 | +29% |
| H.C. Wainwright | Buy | $49.00 | +19% |
| Leerink Partners | Outperform | $46.00 | +12% |
| JPMorgan | Overweight | $41.00 | -0.2% |
| Cantor Fitzgerald | Hold | $31.00 | -25% |
The Guggenheim and Citi high-end targets at $53–$54 are worth engaging because they build in international expansion beyond the U.S. — specifically, potential European FSGS label expansion in late 2026 or early 2027. The Leerink $46 midpoint is a cleaner read on the domestic-only commercial trajectory. The JPMorgan $41 target essentially prices the stock to current levels and assumes orderly launch execution without significant upside from new indications.
For investors parsing the TVTX stock forecast 2026 from targets alone, the implied fair value zone is $42–$49, with the consensus at $44. That is roughly 7–19% upside from today’s price — attractive for a post-catalyst rare-disease name but not extreme. The right sizing is moderate, with patience for a full launch curve to play out through H2 2026 earnings.
FILSPARI Commercial Opportunity and TVTX Stock Forecast 2026
The TVTX stock forecast 2026 is tied almost entirely to FILSPARI’s commercial trajectory in both IgAN and FSGS. Leerink Partners projects FILSPARI can reach $1 billion in peak U.S. sales in FSGS alone, rising to nearly $2 billion across both indications. For context, IgAN sales in 2025 tracked near $220 million annually, suggesting FSGS could roughly triple the current revenue base by 2028–2029.
Total addressable market across both indications exceeds 100,000 U.S. patients at orphan pricing in the $160,000–$180,000 per year range. With 40–50% penetration over 5–7 years — a reasonable rare-disease curve — gross sales potential approaches $6–$8 billion. Applying standard 70–75% gross margins (adjusted for the Ligand royalty) yields roughly $4–$6 billion in potential peak gross profit. That is the economic engine underpinning the TVTX stock forecast 2026 bull case.
Competitive dynamics matter. FILSPARI is currently the only FDA-approved medicine for FSGS, and its orphan designation provides 7 years of market exclusivity in the U.S. plus data exclusivity protections. Chinook Therapeutics (acquired by Novartis) has a competing IgAN asset (atrasentan), but no comparable threat has emerged for FSGS specifically. The competitive moat is durable through 2031 at least.
FAQs About TVTX Stock Forecast 2026
Is TVTX a good stock to buy after FDA approval?
It depends on your risk tolerance. TVTX stock has re-rated sharply on the FSGS approval, and the consensus $44 price target implies only 7% additional upside versus the $41.10 close. However, the Guggenheim $54 and Citigroup $53 targets hint at meaningful optionality if commercial execution continues. Sizing matters — the TVTX stock forecast 2026 setup is attractive for a moderate position rather than a high-conviction bet given the sharp rally into approval.
What is the TVTX stock price target for 2026?
The 10-analyst average price target for TVTX stock is $44.00, with a high of $54.00 (Guggenheim) and a low of $31.00. Median target is $42.50. Simply Wall St’s narrative fair value pegs intrinsic worth at $42.50 (slightly below the high-end street targets). The realistic TVTX stock forecast 2026 landing zone the sell side converges on is $42–$54, implying 2% to 31% upside from today’s price.
What are the bullish and bearish analyst opinions on Travere Therapeutics?
Bulls (Guggenheim $54, Citi $53, H.C. Wainwright $49) highlight FILSPARI’s dual-indication moat across IgAN and FSGS, the $2B combined peak-sales opportunity, and 7-year orphan exclusivity. Bears (Cantor Hold at $31, skeptics of launch timing) cite the stock’s 173% 12-month run, single-product concentration risk, and uncertainty around FSGS prescriber adoption in the first six months. The 8 Buy / 2 Hold split tells you the balance of evidence sits with the bulls right now.
How much could FILSPARI earn in peak sales?
Leerink Partners projects peak U.S. sales of roughly $1 billion in FSGS alone, rising to approximately $2 billion when combined with the existing IgA nephropathy indication. That math assumes 40–50% patient penetration across a combined TAM of 100,000+ U.S. patients at annual list pricing of $160,000–$180,000 before payer rebates. If international expansion into Europe and key Asia markets proceeds on the expected timeline, total peak sales could reach $2.5–$3.0 billion by 2030.
What are the risks to the TVTX stock forecast 2026?
Three main risks. First, single-product concentration — FILSPARI represents more than 90% of forward revenue projections, so any safety or efficacy issue compounds rapidly. Second, launch ramp — FSGS diagnosis is more fragmented than IgAN, and prescription uptake in Q2 and Q3 2026 will determine whether the stock holds current valuation or gives back 15–25%. Third, payer pushback on orphan pricing above $160,000 per year could compress realized net pricing and impair gross margins.
How does TVTX compare to other rare-disease biotechs?
TVTX stock currently trades at roughly 2x estimated peak sales — below historical rare-disease launch-stage multiples at Alnylam (5x), Ionis (4x), and BioMarin (3x). That relative discount is the single most interesting feature of any TVTX stock forecast 2026. If FSGS commercial execution tracks the IgAN precedent, the stock could close the multiple gap and trade closer to 3x peak sales, which would imply prices in the $55–$60 range over a 12–18 month horizon.
Disclaimer
This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Past performance does not guarantee future results. Investors should conduct thorough due diligence and consult qualified financial advisors before making investment decisions.
MEXC is a global cryptocurrency exchange committed to “MEXCmize Your Opportunities.” Serving over 40 million users across 170+ countries, MEXC offers access to more than 3,000 digital assets across spot and derivatives markets. Known for its high liquidity and broad selection of trending tokens, the platform is designed to support both new traders and experienced investors. MEXC also continues to enhance trading efficiency through innovations such as zero trading fees, while prioritizing a secure, user-friendly, and accessible trading experience. Select MEXC as Your 0-fee Gateway To Infinite Opportunities.
